Prothena lays off 63% of employees in fallout from phase 3 amyloidosis drug fail
Prothena is laying off almost two-thirds of its workforce as the Irish biotech navigates the fallout from giving up on its failed amyloidosis drug.

Jun 20, 2025 0
Jun 18, 2025 0
Jun 20, 2025 0
Jun 18, 2025 0
Jun 17, 2025 0
Jun 17, 2025 0
Jun 20, 2025 0
Jun 20, 2025 0
Jun 20, 2025 0
Jun 20, 2025 0
Jun 19, 2025 0
Jun 18, 2025 0
Jun 17, 2025 0
Jun 16, 2025 0
Jun 20, 2025 0
Jun 19, 2025 0
Jun 19, 2025 0
Jun 19, 2025 0
Jun 19, 2025 0
Jun 20, 2025 0
Jun 18, 2025 0
Jun 19, 2025 0
Or register with email
May 12, 2025 0
May 15, 2025 0
May 12, 2025 0
May 12, 2025 0
May 14, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.